Background:
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: February 2019: The following drug classes/subclass and newly approved agents will be reviewed:

Antipsychotic Agents - Atypical: Abilify Mycite

Antimalarials - NA: Arakoda

Anti-Inflammatory Immuno Ophth Agents - Ophth Immuno Agents: Cequa

Oncological Agents - Acute Myelogenous Leukemia: Daurismo

Hematological Agents - WBC Stimulants: Granix Vial

Anti-Inflammatory Immuno Ophth Agents - Ophth Anti-Inflammatory Agents: Inveltys

Oncological Agents - Lung Cancer: Lorbrena

Anti-Inflammatory Immuno Ophth Agents - NA: Oxervate

Metabolic Replacement Agents Miscellaneous - NA: Revcovi

Anticonvulsants - Antimania Agents: Sympazan

Hematological Agents - WBC Stimulants: Udencya

Oncological Agents - NA: Vitrakvi

Glaucoma Agents- NA: Xelpros

Oncological Agents - Acute Myelogenous Leukemia: Xospata

Androgens-Anabolic Steroids - Testosterone Replacement Therapies: Xyosted

Pulmonary-2 Agents - Long Acting Muscarinic Antagonists: Yupelri

RFQ: The RFQ, including UF BPA and UF ADP appendices are attached herein.
There is no pre-proposal teleconference. Rather, questions shall be submitted via e-mail to the Request for Quote (RFQ) Point of Contact stated in Part 2.3, no later than the date stated in Part 2.4. Also, responses to Part 3.4 is required.

POCs: Part 2.3 of the RFQ.
For additional information, search DoD Pharmacy and Therapeutics (P&T) Committee at http://www.health.mil/POD

Bid Protests Not Available